© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
CAR T-Cell Therapy | Clinical
Off-the-Shelf CAR T-Cell Products Show Potential in DLBCL
November 03, 2020
Loretta J. Nastoupil, MD, discusses the use of off-the-shelf chimeric antigen receptor T-cell products for the treatment of patients with diffuse large B-cell lymphoma and other cancers.
Novel Engineered CAR T Cells Show Early Promise in CD19+ B-Cell Malignancies
October 23, 2020
Chimeric antigen receptor T-cell therapy with the novel agent CTX110 showed promising early efficacy and safety as treatment of patients with relapsed or refractory CD19-positive B-cell malignancies who were treated in the phase 1 CARBON clinical trial.
Adoptive CAR T-Cell Therapy Appears Feasible and Safe in mCRPC
October 21, 2020
CART-PSMA-TGFβRd as adoptive chimeric antigen receptor T-cell therapy administered as treatment of patients with metastatic castration-resistant prostate cancer appears safe and feasible.
CAR T-Cell Therapy Appears Promising for Heavily Pretreated Multiple Myeloma
October 12, 2020
Natalie S. Callander, MD, discusses the role of CAR T-cell therapy as treatment of patients with multiple myeloma.
Special Considerations Accompany Newer Agents in R/R B-Cell ALL
October 12, 2020
In the past 5 years, 3 new options have emerged to treat patients with relapsed/ refractory acute lymphoblastic leukemia, providing hope for patients with this disease but also raising clinical questions.
FDA Grants Orphan Drug Designation to Investigational CAR T-Cell Agent in Gastric/GEJ Cancer
October 06, 2020
The FDA granted Orphan Drug designation to the humanized anti-claudin18.2 autologous chimeric antigen receptor T-cell agent, CT041, for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma.
Expert Recognizes Major Advances in Field During Childhood Cancer Awareness Month
September 26, 2020
In an interview with Targeted Oncology, Tanja Gruber, MD, PhD, discussed the advances she has observed in recent years for the treatment of pediatric patients, including the evolving role of CAR T-cell therapy.
Exploring the Future of CAR T-Cell Therapy in Multiple Myeloma
September 17, 2020
C. Ola Landgren, MD, PhD, discusses what is next for chimeric antigen receptor T-cell therapy in the multiple myeloma landscape.
CAR T-Cell Data Call for New Strategies in Treatment of Multiple Myeloma
September 15, 2020
During a presentation at the 2020 Society of Hematologic Oncology Virtual Annual Meeting, Andrzej Jakubowiak, MD, PhD, reviewed clinical trials of CAR T-cell therapy in multiple myeloma and the emergence of CAR T cells against SMALF7, GPRC5D, and CD229.
Early Study Shows Feasibility of Single Vector Multiplexed shRNA for CAR T Cells
September 04, 2020
In an interview with Targeted Oncology, David E. Gilham, PhD, discussed the findings from the single vector multiplexed short-hairpin RNA approach to concurrently knockdown the expression of multiple genes in chimeric antigen receptor T cells when used as treatment of patients with cancer.